Skip Navigation


Annals of Oncology Advance Access originally published online on January 27, 2008
Annals of Oncology 2008 19(3):407-408; doi:10.1093/annonc/mdm594
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
19/3/407    most recent
mdm594v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Horwich, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Horwich, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oxfordjournals.org

editorial

Stage I seminoma and carboplatin risks

A. Horwich

Department of Clinical Oncology, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK

(E-mail: alan.horwich@icr.ac.uk)

The first 10% of the full text of this article appears below.

Should the report of carboplatin morbidity by Powles et al. [1] in this issue influence the management of patients with stage I seminoma post-orchidectomy? In a study of 199 patients treated with one or two cycles of adjuvant carboplatin as a single agent, and followed for between 0.1 and 20.1 years (median 9), the analysis showed no excess mortality compared with the age and sex-matched UK population with 95% confidence intervals (CIs) on their standardised mortality ratio (SMR) from 0.36 to 1.83. . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?